

ORIGINAL ARTICLE

Prevalence and Predictors of Heart Failure among Patients on Maintenance Hemodialysis Therapy at Tertiary Care Hospitals

JAWAD ABBAS¹, MUHAMMAD ARSHAD², PARVEEN AKHTAR³, ARSHAD ALI SHAH⁴, SYED DILBAHAR ALI SHAH⁵, KHAN GUL⁶

¹Senior Registrar, Interventional Cardiology, PNS Shifa Hospital, Karachi

²Cardiologist, King Abdullah Teaching Hospital, Mansehra

³Associate Professor, National Institute of Cardiovascular Disease, Karachi

⁴Assistant Professor, Dow University of Health and Sciences/Civil Hospital, Karachi

⁵Assistant Professor, Dow University of Health and Sciences/Civil Hospital, Karachi

⁶Medical Officer, Al Khair Medical Centre Saddar, Peshawar

Corresponding author: Muhammad Arshad, Email: dr-arsh@hotmail.com, Cell: +923335055036

ABSTRACT

Background and Aim: The incidence of heart failure among hemodialysis patients predicts poor outcomes. Hypertension, aging, and diabetes mellitus are traditional risk factors for heart failure which may not predict heart failure accurately. Heart failure might be caused by other factors. The present study aims to determine the prevalence and predictors of heart failure among patients on maintenance hemodialysis.

Methodology: This cross-sectional study was carried out on 142 hemodialysis patients in the department of Cardiology, PNS Shifa Hospital Karachi and King Abdullah Teaching hospital Mansehra for duration of six months from 5th March 2021 to 4th September 2021. All the patients having age above 16 years and who underwent at least three months of dialysis therapy were enrolled. Patients with severe respiratory distress and mentally incapacitated were excluded. Questionnaire-based Pro-forma was used for collecting patient's demographic details, clinical details such as human immunodeficiency virus (HIV) disease, heart failure symptoms, hyperlipidemia, angina, and presence of diabetes, etc., and dialysis-related clinical information. Stadiometer and standard weight scale were used for height and post-dialysis weight also known as dry weight respectively. A monthly dose of erythropoietin (EPO) was taken from medical records. Based on the blood sample, albumin, ferritin, urea, complete blood count, C-reactive protein (CRP), and total cholesterol were measured. SPSS version 21 was used for data analysis.

Results: Out of 142 hemodialysis patients, 105 (73.9%) were male and 37 (26.1%) were females. Overall mean age was 46.74 ± 11.62 years. Of the total 142 patients, the prevalence of hypertension and diabetes mellitus was 138 (97.2%) and 73 (51.4%) respectively. The incidence of heart failure was 21 (14.8%). The incidence of hypertension, anemia, and angina were heart failure autonomous prognosticators on multivariate analysis. A higher score of malnutrition inflammation and resistance index for erythropoietin was found in heart failure patients.

Conclusion: Our study found that heart failure is significantly associated with anemia, angina, and hypertension in hemodialysis patients. Malnutrition–inflammation complex and erythropoietin resistance were more prevalent in patients with heart failure. These conditions necessitate a thorough cardiac evaluation and appropriate treatment.

Keywords: Heart Failure, Hemodialysis, Hypertension, Angina

INTRODUCTION

Hemodialysis patients who have heart failure are more likely to have a bad outcome. Traditional risk factors for heart failure, such as hypertension, diabetes, and age, may not correctly predict heart failure. Other causes [1, 2] can contribute to heart failure. Chronic renal disease patients have a higher mortality and morbidity rate than the general population [3, 4]. There is a substantial mortality risk associated with left ventricular hypertrophy in patients with chronic kidney disease [5]. Chronic inflammation, anaemia, vascular calcifications, and changes in recurrent fluid volume are among the diseases that patients receiving hemodialysis (HD) experience [6]. Congestive heart failure affects 36% of people in the United States, according to new data [7]. Hypertension, atherosclerosis measures, ageing, and diabetes mellitus were all strongly linked to these individuals' heart failure. The MICS (malnutrition inflammation complex syndrome) was accompanied by increasing atherosclerosis in HD patients [7, 8].

Inflammation and malnutrition are two of the most common issues for hemodialysis patients, and both are

associated with poor outcomes [8, 9]. Malnutrition Inflammation Complex Syndrome, the combination of these two conditions, predicts an increase in the death rate of hemodialysis patients (MICS). MICS have been linked to a higher prevalence of heart failure in 42.4 percent of Brazilians and 61.2 percent of Kenyans in a prior study. Hyper-metabolism, metabolic acidosis produced by chronic inflammation, and protein breakdown by chronic inflammation are all variables that contribute to malnutrition in dialysis patients [8, 12]. CRP, an inflammatory marker, has been associated to HD sufficiency [13]. Pro-inflammatory cytokines produced by the uremic milieu have been shown to cause chronic inflammation in up to 50% of hemodialysis patients [14]. These cytokines impair protein synthesis and speed up atherosclerosis. Heart failure can be exacerbated by the retention of inter-dialytic fluid in patients with MICS [15]. Heart failure indicators in dialysis patients are not well studied. Thus, the current study was done to examine the prevalence and predictors of heart failure in patients receiving continuous hemodialysis.

METHODOLOGY

This cross-sectional study was carried out on 142 hemodialysis patients in the department of Cardiology, PNS Shifa Hospital, Karachi and King Abdullah Teaching Hospital, Mansehra for duration of six months from 5th March 2021 to 4th September 2021. All patients over the age of 16 who had dialysis treatment for at least three months were included in the study. The institution's ethics committee gave its approval. Each patient signed an informed consent form. Psychologically and physically disabled individuals were excluded from the study. It was used to collect demographic and clinical information about the patient (such as HIV status and heart failure symptoms), as well as dialysis-related clinical information (such as the existence of diabetes). Standard weight scales were utilised for height and post-dialysis dry weight, respectively. Medical data indicated that erythropoietin (EPO) should be taken once a month. In the blood sample, albumin, ferritin, urea, complete blood count, C-reactive protein (CRP), and total cholesterol were determined.

Heart failure includes nocturnal dyspnea, orthopnea, nocturnal cough, ankle edoema, and exertion dyspnea as main and minor criteria. Diastolic pressure above 90 mm Hg, and systolic above 140 mm Hg, were classed as hypertension. The malnourished inflammation score was calculated using ten criteria (MIS). 2. Intake of dietary supplements, 3. Weight loss after three months, 3. GI symptoms, 4. Nutritional impairment related with functional impairment, 5. Comorbidity status, 6. Fat loss extent, 7. Muscle loss extent, 8. BMI, 9. Serum albumin levels, and 10. Serum transferrin levels range from 0 to 3, with 0 indicating normal levels and 3 indicating severe cases. The data was analysed using SPSS version 20. The proportion of categorical variables to heart failure outcomes was compared using the Chi-square test. It was determined that p0.3 was significant in a univariate study, whereas p0.05 was declared significant in a multivariate analysis.

RESULTS

105 of the 142 hemodialysis patients were male, and 37 were female (26.1%). The average age of the participants was 46.74 years, with a standard deviation of 11.62 years. Hypertension and diabetes were found in 138 (97.2 percent) and 73 (51.4 percent) of the 142 patients, respectively. The rate of heart failure was 21 per 100,000 people in the study (14.8 percent). Autonomous prognosticators for heart failure included the prevalence of

high blood pressure, anaemia, and angina. Heart failure patients had a greater erythropoietin resistance and malnourished inflammation index score. The prevalence of hyperlipidemia, HIV disease, and hepatitis B infections was 7 (4.9%), 11 (7.7%), and 9 (6.34%) respectively. Anti-hypertensive medications were used by 126 (88.7%) among hypertension patients. Out of 126 anti-hypertension drugs users, the incidence of calcium channel blockers, angiotensin receptor blockers, beta-blockers, and hydralazine were 73 (51.4%), 8 (5.6%), 31 (21.8%), and 56 (39.4%) respectively. The pre-dialysis and post-dialysis systolic and diastolic pressure were 152 ± 20 mm Hg and 84 ± 11 mm Hg, and 150 ± 21 mm Hg and 85 ± 10 mm Hg respectively. The prevalence of pre-dialysis systolic (>140 mm Hg) and diastolic hypertension (>90 mm Hg) was 74.9% and 26.3% respectively. Figure-1 illustrate the incidence of heart failure and no-failure in the patients. Gender distribution is shown in Figure-2. Different predictors for hemodialysis patients heart failure is shown in Table-1. The prevalence of different factors are shown in Figure-3.




Figure 1: Prevalence of heart failure among hemodialysis patients (n=142)




Figure 2: Gender distribution (n=142)

Table 1: Predictive factors for heart failure in hemodialysis (n=142)

Parameters	Unadjusted ratio (95% CI)	p-value	Adjusted ratio (95% CI)	P-value
Age (years)	1.02 (0.89-1.05)	0.19	1.02 (0.92-1.06)	0.29
Gender (Male)	1.05 (0.31-3.12)	0.89		
Diabetes Mellitus	2.01 (0.69-5.43)	0.20	1.79 (0.48-5.89)	0.41
Angina	10.5 (2.10-45.8)	<0.12	5.89 (1.04-32.8)	<0.05
Hyperlipidemia	1.03 (0.10-8.9)	0.97		
Pre-dialysis hypertension	4.32 (0.45-32.8)	0.21	6.7 (0.30-159)	0.19
Post-dialysis hypertension	3.12 (0.69-13.5)	0.12	1.79 (0.31-11.9)	0.52
HIV disease	0.53 (0.05-4.59)	0.59		
Duration of HD	1.03 (0.93-1.01)	0.61		
BMI (kg/m2)	0.92 (0.79-1.09)	0.51		
Albumin (g/dl)	0.85 (0.27-2.51)	0.79		
Hemoglobin (g/dl)	0.71 (0.52-0.89)	<0.05	0.69 (0.5-0.97)	<0.05
Malnutrition Inflammation Score	1.09 (1.02-1.20)	<0.05	1.01 (0.89-1.21)	0.59




Figure 3: Prevalence of heart failure different factors

DISCUSSION

In the present cross-sectional study, 142 hemodialysis patients were enrolled to determine the prevalence and prediction factors of heart failure among hemodialysis patients. Male were more prevalent than females. The incidence of heart failure occurs in 21 (14.8%) patients. Based on multivariate analysis, the severity index was significantly predicted by the longer duration of hemodialysis disease whereas the negative predictor was hypercholesterolemia. MICS patients had lower mean BMI, total cholesterol, creatinine levels, transferrin, albumin, and hemoglobin. The heart failure found in the recent study was lower than earlier study which might be explained by an adequate supply of blood through dialysis and better control of fluid volume [16]. The cardiac load increase may be caused by excessive fluid which in turn rouses the renin-angiotensin-aldosterone system (RAAS), remodeling the left ventricular [17, 18]. LV hypertrophy might be caused by overstimulation of Anemia-induced sympathetic which further causes diastolic dysfunction [19]. Erythropoietin stimulating agents for anemia is a mainstay, however, in certain cases like iron deficiency concomitant and chronic inflammation, it may respond insignificantly [20, 21].

Patients with higher MIS are significantly associated with heart failure presence. It might be caused by interdialytic fluid increased retention that exists in MIC patients [22]. The MIC presence in patients might control adequate fluid that causes ongoing weight loss [23]. The risk of fluid overload is higher in low weight or body mass index patients as founded by a previous study [24]. Increased cytokines such as TNF- α and MIC lead to hypoalbuminemia promotes a shift of fluid from the intravascular compartment that leads to congestive heart failure [25].

Intra-dialytic hypertension is thought to result from excessive inter-dialytic weight gain [26]. Intradialytic hypertension was reported to be considerably linked with the development of heart failure in our study. Sodium retention, RAAS, endothelial dysfunction, and sympathetic over-stimulation have also been associated to intra-dialytic hypertension. All of these factors contribute to LV remodelling, raising the risk of heart failure [27].

Malnutrition and inflammation both contribute to atherosclerosis and are thus linked as the Malnutrition–Inflammation–Atherosclerosis (MIA) syndrome, which is

associated with poor cardiovascular outcomes [28]. Coronary atherosclerosis is common in HD patients, resulting in gradual loss of myocardial and systolic dysfunction [29]. The risk of heart failure development increases approximately six-fold in angina patients as reported in the current study. Patients with low cholesterol levels, on the other hand, have advanced CVD. Heart failure patients had lower cholesterol levels. This is resemble to reverse epidemiology concept, which is primarily associated with oxidative stress, chronic inflammation, and the resulting dysfunction of endothelial and myocardial [30]. Unlike in the general population, conventional risk factors do not significantly correlate with CVD in patients with advanced CKD [31]. Similarly, ageing, hypertension, diabetes, and hyperlipidemia were not associated with the incidence of heart failure; instead, MICS was associated with HF. Anti-oxidants and statins may aid in inflammatory syndrome reduction that promotes myocardial and atherosclerosis damages [32]. Inflammation-related middle molecules clearance and high-flux hemodialysis can improve anemia of refractory erythropoietin [33].

CONCLUSION

In our study, we found that heart failure is significantly related with anaemia, angina, and hypertension in individuals undergoing hemodialysis. Patients with heart failure had higher rates of malnutrition–inflammation complex and erythropoietin resistance than the general population. These circumstances need a thorough cardiac evaluation and the administration of appropriate therapy.

REFERENCES

1. Chillo P, Mujuni E (2018) Prevalence and predictors of left ventricular dysfunction among patients with chronic kidney disease attending Muhimbili National Hospital in Tanzania—a cross-sectional study. *Res Rep CliCardiol* 21(9):11–21
2. Vlatković V, Trbojević-Stanković J, Stojimirović B (2017) Relationship between Malnutrition-inflammation complex syndrome and fluid balance in maintenance hemodialysis patients. *UrolNephrol Open Access J* 4(5):00144
3. Bramania PK, Ruggajo P, Bramania R, Mahmoud M, Furia FF (2020) Prevalence of malnutrition inflammation complex syndrome among patients on maintenance haemodialysis at Muhimbili National Hospital in Tanzania: a cross-sectional study. *BMC Nephrol* 21(1):1–1
4. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis*. 2019;73(3 Suppl 1):A7–8.
5. McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL. Intensive hemodialysis, left ventricular hypertrophy, and cardiovascular disease. *Am J Kidney Dis*. 2016;68(5S1): S5–S14.
6. Loutradis C, Sarafidis PA, Papadopoulos CE, Papagianni A, Zoccali C. The ebb and flow of echocardiographic cardiac function parameters in relationship to hemodialysis treatment in patients with ESRD. *J Am Soc Nephrol*. 2018;29(5): 1372–81.
7. Tsilonis K, Sarafidis PA, Kamperidis V, Loutradis C, Georgianos PI, Imprialos K, et al. Echocardiographic parameters during long and short interdialytic intervals in hemodialysis patients. *Am J Kidney Dis*. 2016;68(5):772–81.

8. Sarafidis PA, Kamperidis V, Loutradis C, Tsilonis K, Mpoutsouki F, Saratzis A, et al. Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes? *Nephrol Dial Transplant*. 2017;32(8):1402–9.
9. Alexandrou ME, Loutradis C, Schoina M, Tzanis G, Dimitriadis C, Sachpekidis V, et al. Ambulatory blood pressure profile and blood pressure variability in peritoneal dialysis compared with hemodialysis and chronic kidney disease patients. *Hypertens Res*. 2020;43(9):903–13.
10. Alexandrou ME, Loutradis C, Balafa O, Theodorakopoulou M, Tzanis G, Bakaloudi D, et al. A comparative study of ambulatory central hemodynamics and arterial stiffness parameters in peritoneal dialysis and hemodialysis patients. *J Hypertens*. 2020;38(12):2393–403.
11. Alexandrou ME, Gkaliagkousi E, Loutradis C, Dimitriadis C, Mitsopoulos E, Lazaridis A, et al. Hemodialysis and peritoneal dialysis patients have severely impaired post-occlusive skin forearm vasodilatory response assessed with laser speckle contrast imaging. *Clin Kidney J*. 2020;14:1419–27.
12. Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *Nephrol Dial Transplant*. 2017;32(4):620–40.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16(3):233–70.
14. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277–314.
15. Adamska-Welniczka A, Welnicki M, Krzesinski P, Niemczyk S, Lubas A. Multi-method complex approach for hydration assessment does not detect a hydration difference in hemodialysis versus periton. *Open Cardiovasc Med J*. 2016; 10:171–8.
16. Ellouali F, Berkchi F, Bayahia R, Benamar L, Cherti M. Comparison of the effects of dialysis methods (haemodialysis vs peritoneal dialysis) on diastolic left ventricular function dialysis methods and diastolic function. *Open Cardiovasc Med J*. 2016; 10:171–8.
17. Ito H, Nakata J, Inoshita H, Ishizaka M, Tomino Y, Suzuki Y. Relationship among left ventricular hypertrophy, cardiovascular events, and preferred blood pressure measurement timing in hemodialysis patients. *J Clin Med*. 2020;9(11):351.
18. Paoletti E, De Nicola L, Gabbai FB, Chiodini P, Ravera M, Pieracci L, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. *Clin J Am Soc Nephrol*. 2016;11(2):271–9.
19. Karpetas A, Sarafidis PA, Georgianos PI, Protogerou A, Vakianis P, Koutroumpas G, et al. Ambulatory recording of wave reflections and arterial stiffness during intra- and interdialytic periods in patients treated with dialysis. *Clin J Am Soc Nephrol*. 2015;10(4):630–8.
20. Koutroumpas G, Georgianos PI, Sarafidis PA, Protogerou A, Karpetas A, Vakianis P, et al. Ambulatory aortic blood pressure, wave reflections and pulse wave velocity are elevated during the third in comparison to the second interdialytic day of the long interval in chronic haemodialysis patients. *Nephrol Dial Transplant*. 2015;30(12):2046–53.
21. Georgianos PI, Sarafidis PA, Haidich AB, Karpetas A, Stamatiadis D, Nikolaidis P, et al. Diverse effects of interdialytic intervals on central wave augmentation in haemodialysis patients. *Nephrol Dial Transplant*. 2013;28(8):2160–9.
22. Flythe JE, Chang TI, Gallagher MP, Lindley E, Madero M, Sarafidis PA, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2020;97(5):861–76.
23. Loutradis C, Sarafidis PA, Ekart R, Papadopoulos C, Sachpekidis V, Alexandrou ME, et al. The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. *Kidney Int*. 2019;95(6):1505–13.
24. Zoccali C, Torino C, Mallamaci F, Sarafidis P, Papagianni A, Ekart R, et al. A randomized multicenter trial on a lung ultrasound guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. *Kidney Int*. 2021. <http://dx.doi.org/10.1016/j.kint.2021.07.024>.
25. Halle MP, Nelson M, Kaze FF, Jean Pierre NM, Denis T, Fouda H, Ashuntantang EG. Non-adherence to hemodialysis regimens among patients on maintenance hemodialysis in sub-Saharan Africa: an example from Cameroon. *Renal Failure*. 2020 Jan 1;42(1):1022-8.
26. Halle MP, Hilaire D, Francois KF, Denis T, Hermine F, Gloria AE. Intradialytic hypotension and associated factors among patients on maintenance hemodialysis: A single-center study in Cameroon. *Saudi Journal of Kidney Diseases and Transplantation*. 2020 Jan 1;31(1):215.
27. Anu Abraham. The Prevalence of Malnutrition Inflammation Complex Syndrome in maintenance hemodialysis patients at Charlotte Maxeke Johannesburg hospital. (Doctoral dissertation), 2019. University of the Witwatersrand, Johannesburg, South Africa. [Cited 2020 April 6]. Available from <https://hdl.handle.net/10539/28148>
28. Moussa HD, Tondi ZM, Kane Y, Sani MA, Abdou I, Touré I, Illa A, Omar AE. Assessing the Nutritional Status of Hemodialysis Patients in Sub-Saharan Africa: Experience of Two Hemodialysis Centers in Niger. *Open Journal of Nephrology*. 2016 Nov 11; 6(4):161-6.
29. Halle MP, Zebaze PN, Mbofung CM, Kaze F, Mbiat H, Ashuntantang G, Kengne AP. Nutritional status of patients on maintenance hemodialysis in urban sub-Saharan Africa: evidence from Cameroon. *Journal of nephrology*. 2018 Oct 1; 27(5):545-53.
30. Valencia VC, Rodríguez OM, Sandoval ME, Bermúdez JA, Castellanos SG, de la Cruz CO, Córdova MA. Prevalence of malnutrition-inflammation complex syndrome and its correlation with thyroid hormones in chronic haemodialysis patients. *Nefrología (English Edition)*. 2018 Jan 1; 38(1):57-63.
31. Omari AM, Omari LS, Dagash HH, Sweileh WM, Natour N, Sa'ed HZ. Assessment of nutritional status in the maintenance of haemodialysis patients: a cross-sectional study from Palestine. *BMC nephrology*. 2019 Dec 1; 20(1):92.
32. Lopes MB, Silva LF, Lopes GB, Penalva MA, Matos CM, Robinson BM, Lopes AA. Additional Contribution of the Malnutrition-Inflammation Score to Predict Mortality and Patient-Reported Outcomes as Compared With Its Components in a Cohort of African Descent Hemodialysis Patients. *Journal of Renal Nutrition*. 2017; 27(1):45–52.
33. MatikoGiabe. Malnutrition Inflammation Complex Syndrome among ambulant End Stage Disease patients on Maintenance Hemodialysis at Kenyatta National Hospital. (Master's dissertation), 2016. University of Nairobi, Kenya.